COX-2 expression in thymomas and thymic carcinomas: a novel therapeutic target? by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Diagnostic Pathology
Open AccessOral presentation
COX-2 expression in thymomas and thymic carcinomas: a novel 
therapeutic target?
RJ Rieker*1, PhA Schnabel1, G Mechtersheimer1, M Thomas2, H Dienemann2, 
P Schirmacher1 and MA Kern1
Address: 1Institut für allgemeine Pathologie, Universitätsklinikum Heidelberg, Germany and 2Thoraxklinik Rohrbach am Universitätsklinikum 
Heidelberg, Germany
* Corresponding author    
Aims
The treatment of advanced stage thymomas and thymic
carcinomas is multimodal and includes surgery as well as
radiochemotherapy. New therapeutic targets such as
EGFR and c-kit are currently under investigation. A
number of studies have shown a protumorigenic potential
of Cyclooxygenase-2 (COX-2), an enzyme of the prostag-
landin metabolism, in a variety of human malignancies,
but so far it is unknown whether COX-2 is expressed in
epithelial tumors of the thymus.
Methods
Using tissue microarrays, the expression of COX-2, micro-
somal-PGES-1 and -PGES-2 (mPGES-1 and mPGES-2), as
well as EGFR was evaluated in thirty-four cases of different
subtypes of thymoma and thymic carcinomas. Further-
more, twenty-seven additional cases of thymomas and
thymic carcinomas were analysed by COX-2 western
immunoblot analysis and compared with six normal
thymi from young children.
Results
COX-2 was expressed in all thymoma- and thymic carci-
noma subtypes. When measuring the optical color inten-
sity, no significant differences between the subtypes could
be detected. A weak correlation between the expression of
COX-2, mPGES-1 and mPGES-2 as well as EGFR was
found. Western blot analysis of COX-2 expression
revealed an up-regulation compared with normal thymus.
Conclusion
COX-2 is expressed in all subtypes of thymomas and
thymic carcinomas and represents therefore a potential
novel therapeutic target beside EGFR and c-kit. A com-
bined therapy using COX-2 inhibitors in addition to the
evolving anti-EGFR antibody therapy may be considered
as treatment option, especially when there is no response
to established chemotherapeutic schemes, since this com-
bination has a positive impact on the treatment of other
malignancies.
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